K Pharma (TSE:4896) COGS-to-Revenue : 0.00 (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is K Pharma COGS-to-Revenue?

K Pharma's Cost of Goods Sold for the three months ended in Mar. 2024 was 円0 Mil. Its Revenue for the three months ended in Mar. 2024 was 円0 Mil.

K Pharma's COGS to Revenue for the three months ended in Mar. 2024 was 0.00.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. K Pharma's Gross Margin % for the three months ended in Mar. 2024 was N/A%.

K Pharma COGS-to-Revenue Historical Data

The historical data trend for K Pharma's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

K Pharma COGS-to-Revenue Chart

K Pharma Annual Data

Trend

Dec21

Dec22

Dec23

COGS-to-Revenue

0.09

K Pharma Quarterly Data
	Dec21	Dec22	Jun23	Sep23	Dec23	Mar24
COGS-to-Revenue	Get a 7-Day Free Trial			-	-	-	-	-

K Pharma COGS-to-Revenue Calculation

K Pharma's COGS to Revenue for the fiscal year that ended in Dec. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	90	/	1000
	=	0.09

K Pharma's COGS to Revenue for the quarter that ended in Mar. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0	/	0
	=

K Pharma (TSE:4896) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

K Pharma's Gross Margin % for the three months ended in Mar. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0 / 0
	=	N/A %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

K Pharma COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of K Pharma's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

K Pharma (TSE:4896) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » K Pharma Inc (TSE:4896) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

7-7-7 Roppongi, Minato-ku, Tokyo, JPN, 106-0032

Website

https://en.kpharma.co.jp

K Pharma Inc is a company involved in Research, development, manufacturing, sales and marketing of pharmaceutical products and regenerative medicine products. It is involved in studying of iPs cells in regnerative medecine to treat neurological conditions such as cerebral infarction and SCI.

K Pharma (TSE:4896) Headlines

No Headlines